Literature DB >> 9138606

Clinical significance of bcl-2 gene expression in human breast cancer tissues.

S Kobayashi1, H Iwase, Y Ito, H Yamashita, H Iwata, T Yamashita, K Ito, T Toyama, T Nakamura, A Masaoka.   

Abstract

The expression of estrogen receptor (ER) and bcl-2 (Bcl-2), an apoptosis protective oncogene, in normal and cancerous breast duct epithelia was immunohistochemically examined in fresh frozen tumor tissues from 142 Japanese breast cancer patients. The clinico-pathological characteristics and the disease free survival of the patients were analyzed. The expression of both the proteins was also observed in intraductal components of breast cancer. Although less than 1% of normal duct epithelia expressed ER, Bcl-2 was diffusely expressed. The expression of both these proteins in breast cancer significantly correlated with each other. Their expression significantly correlated negatively with tumor size but not with lymph node status. The papillo-tubular sub-type of invasive ductal carcinoma expressed Bcl-2 significantly more frequently than the solid-tubular sub-type. Patients with Bcl-2 expressing tumors survived without recurrence significantly more than those with tumors exhibiting reduced expression. Papillary-cribriform type intraductal components expressed both those proteins more often than the solid-comedo type.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138606     DOI: 10.1023/a:1005760013810

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Plasma bcl-2 and nitric oxide: possible prognostic role in patients with metastatic breast cancer.

Authors:  H E Gaballah; I Abdel Salam; N Abdel Wahab; O M Mansour
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

2.  Implications of Bit1 and AIF overexpressions in esophageal squamous cell carcinoma.

Authors:  Tianli Fan; Fang Tian; Shanyong Yi; Yang Ke; Shengna Han; Lirong Zhang; Hongtao Liu
Journal:  Tumour Biol       Date:  2013-08-17

3.  Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells.

Authors:  S S Larsen; I Heiberg; A E Lykkesfeldt
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

4.  Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.

Authors:  M G Daidone; A Luisi; G Martelli; E Benini; S Veneroni; G Tomasic; G De Palo; R Silvestrini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 5.  How cell death shapes cancer.

Authors:  V Labi; M Erlacher
Journal:  Cell Death Dis       Date:  2015-03-05       Impact factor: 8.469

6.  Evaluation of in vitro anticancer activity of Ocimum basilicum, Alhagi maurorum, Calendula officinalis and their parasite Cuscuta campestris.

Authors:  Mandana Behbahani
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

7.  BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.

Authors:  Mark D Zarella; Rebecca C Heintzelman; Nikolay K Popnikolov; Fernando U Garcia
Journal:  BMC Clin Pathol       Date:  2018-12-18

8.  Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.

Authors:  Yasuhiro Okumura; Yutaka Yamamoto; Zhenhuan Zhang; Tatsuya Toyama; Teru Kawasoe; Mutsuko Ibusuki; Yumi Honda; Ken-ichi Iyama; Hiroko Yamashita; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-10-06       Impact factor: 4.430

9.  Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue.

Authors:  Li-Shu Wang; Yi-Wen Huang; Suling Liu; Pearlly Yan; Young C Lin
Journal:  BMC Cancer       Date:  2008-07-24       Impact factor: 4.430

10.  Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

Authors:  Hiroko Yamashita; Mariko Nishio; Tatsuya Toyama; Hiroshi Sugiura; Zhenhuan Zhang; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.